Financial Performance - For the year ended December 31, 2024, the Group reported revenue of HK$1,913,162,000, a slight decrease of 0.6% compared to HK$1,923,964,000 in 2023[14]. - The Group's gross profit decreased by 14.8% to HK$527,619,000 from HK$618,962,000 in 2023[14]. - The loss for the year attributable to equity holders of the Company was HK$135,163,000, a significant decline of 318.0% compared to a profit of HK$61,998,000 in 2023[14]. - Adjusted profit for the year increased by 11.9% to HK$89,410,000 from HK$79,916,000 in the previous year[14]. - Adjusted EBITDA rose by 2.5% to HK$344,211,000 compared to HK$335,794,000 in 2023[14]. - The gross profit margin decreased to 27.6% from 32.2%, reflecting a decline of 4.6 percentage points[14]. - The adjusted profit attributable to equity holders increased by 5.7% to HK$58.7 million in 2024, compared to HK$55.6 million in 2023[21]. - The adjusted profit attributable to equity holders of the Company for 2024 was HK$58.7 million, up from HK$55.6 million in 2023, while total revenue decreased to HK$1,913.2 million from HK$1,924.0 million[35][36]. - The overall loss for the Mainland China ophthalmic business decreased from HK$75.7 million in 2023 to HK$47.1 million in 2024, excluding impairment losses[50]. Revenue Breakdown - Core medical service revenue increased by 0.5% to HK$1,913,162,000 from HK$1,904,531,000 in the previous year[14]. - Revenue from the ophthalmic business decreased by 4.3% to HK$1.37 billion in 2024, primarily due to reduced demand for refractive surgeries[24]. - Revenue from Hong Kong decreased by 3.3% to HK$901.6 million in 2024 from HK$932.1 million in 2023, primarily due to cautious consumer trends[60]. - Revenue from ophthalmic services in Mainland China increased by 4.0% to HK$1,011.6 million in 2024 from HK$972.4 million in 2023, with a 6.1% increase in RMB terms[61]. - Revenue from dental services in Shenzhen surged by 20.8% to HK$464.6 million in 2024 from HK$384.7 million in 2023[65]. - Revenue from the use of Elderly Health Care Vouchers at Shenzhen CKJ Hospital amounted to HK$15.1 million from August 14 to December 31, 2024[53]. - Revenue from oncology and other medical services decreased to approximately HK$38.1 million, representing 2.0% of total revenue[91]. - Revenue from sales of vision aid products decreased by 3.8% to HK$156.4 million in 2024, mainly due to reduced demand in Mainland China[92]. Operational Challenges and Strategies - The Group faced challenges including a complex global macroeconomic environment and intense industry competition, prompting a refinement of business strategies[19]. - The Group aims to identify new avenues for growth amidst the evolving market landscape[19]. - The Group's operational strategy includes optimizing its organizational structure and refining management to improve profitability and efficiency[41][47]. - The company plans to invest in innovative healthcare solutions, including a fair value gain of HK$111.1 million from its investment in Health Hope Pharma Limited[30]. Capital Expenditures and Financial Position - Capital expenditures in 2024 totaled HK$444.7 million, primarily for the addition of right-of-use assets and equipment for hospitals and clinics[127]. - As of December 31, 2024, the Group's total capital commitments amounted to approximately HK$31.9 million, a decrease from HK$107.2 million in 2023, mainly related to property and hospital lease renovations in Shenzhen Ping Shan[133]. - The Group's debt-to-equity ratio is not applicable as of December 31, 2024, due to a net cash position, consistent with 2023[134]. - The Group reported cash and cash equivalents of HK$423.1 million, short-term bank deposits of HK$29.0 million, and bank borrowings of HK$29.2 million, with most borrowings denominated in US dollars, Renminbi, or Hong Kong dollars[155][158]. Future Outlook and Expansion Plans - The outlook for ophthalmic services in Hong Kong remains strong due to an aging population, while challenges persist in Mainland China's ophthalmic business due to changing consumer patterns[152]. - The Group plans to capitalize on business opportunities in the dental sector in Shenzhen and the medical business in Luohu, Shenzhen, driven by the trend of cross-border consumption[153]. - The C+ Health CKJ (Shenzhen) Hospital is set to open in January 2025, offering dental and multi-specialty medical services to meet the needs of Hong Kong's elderly population[28]. - A strategic agreement was signed for the construction of a "Hong Kong-style" private hospital near Luohu port, expected to open in January 2025[54]. Management and Governance - Dr. Dennis Lam has been appointed as a "Justice of the Peace" in Hong Kong since 2004 and has served as a Deputy of the National People's Congress of China since 2008[193]. - Ms. Li Xiaoting has been the general manager of the eye center in Hong Kong since January 2012 and the general manager of Shenzhen C-MER Hospital since March 2013[195]. - Dr. Lee Yau Wing Vincent has been practicing since January 2012 and is the Head of Hong Kong Operation[199].
希玛医疗(03309) - 2024 - 年度财报